GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Luoxin Pharmaceutical Group Stock Co Ltd (OTCPK:SLUXY) » Definitions » Shiller PE Ratio

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Shiller PE Ratio : 9.09 (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shandong Luoxin Pharmaceutical Group Stock Co Shiller PE Ratio?

As of today (2024-04-26), Shandong Luoxin Pharmaceutical Group Stock Co's current share price is $11.00. Shandong Luoxin Pharmaceutical Group Stock Co's E10 for the quarter that ended in Mar. 2017 was $1.21. Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio for today is 9.09.

The historical rank and industry rank for Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio or its related term are showing as below:

SLUXY's Shiller PE Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.12
* Ranked among companies with meaningful Shiller PE Ratio only.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Shandong Luoxin Pharmaceutical Group Stock Co's adjusted earnings per share data for the three months ended in Mar. 2017 was $0.198. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.21 for the trailing ten years ended in Mar. 2017.

Shiller PE for Stocks: The True Measure of Stock Valuation


Shandong Luoxin Pharmaceutical Group Stock Co Shiller PE Ratio Historical Data

The historical data trend for Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Luoxin Pharmaceutical Group Stock Co Shiller PE Ratio Chart

Shandong Luoxin Pharmaceutical Group Stock Co Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shandong Luoxin Pharmaceutical Group Stock Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 11.25

Competitive Comparison of Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio falls into.



Shandong Luoxin Pharmaceutical Group Stock Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=11.00/1.21
=9.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Luoxin Pharmaceutical Group Stock Co's E10 for the quarter that ended in Mar. 2017 is calculated as:

For example, Shandong Luoxin Pharmaceutical Group Stock Co's adjusted earnings per share data for the three months ended in Mar. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2017 (Change)*Current CPI (Mar. 2017)
=0.198/103.2000*103.2000
=0.198

Current CPI (Mar. 2017) = 103.2000.

Shandong Luoxin Pharmaceutical Group Stock Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200512 0.098 75.666 0.134
200612 0.127 77.793 0.168
200712 0.271 82.911 0.337
200803 0.093 85.485 0.112
200806 0.108 85.058 0.131
200809 0.126 85.057 0.153
200812 0.107 83.956 0.132
200903 0.127 84.457 0.155
200906 0.149 83.615 0.184
200909 0.152 84.369 0.186
200912 0.218 85.386 0.263
201003 0.257 86.316 0.307
201006 0.204 85.886 0.245
201009 0.208 87.267 0.246
201012 0.261 89.289 0.302
201103 0.318 91.154 0.360
201106 0.107 91.612 0.121
201109 0.248 92.711 0.276
201112 0.257 92.885 0.286
201203 0.036 94.367 0.039
201206 0.292 93.495 0.322
201209 0.310 94.482 0.339
201212 0.204 95.237 0.221
201303 0.344 96.372 0.368
201306 0.290 95.984 0.312
201309 0.261 97.332 0.277
201312 0.249 97.624 0.263
201403 0.324 98.600 0.339
201406 0.263 98.200 0.276
201409 0.236 98.900 0.246
201412 0.355 99.000 0.370
201503 0.285 99.900 0.294
201506 0.306 99.500 0.317
201509 0.300 100.500 0.308
201512 0.388 100.600 0.398
201603 0.297 102.200 0.300
201606 0.203 101.400 0.207
201609 9.153 102.400 9.225
201612 0.274 102.600 0.276
201703 0.198 103.200 0.198

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Shandong Luoxin Pharmaceutical Group Stock Co  (OTCPK:SLUXY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Shandong Luoxin Pharmaceutical Group Stock Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Shandong Luoxin Pharmaceutical Group Stock Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Business Description

Traded in Other Exchanges
N/A
Address
Shandong Luoxin Pharmaceutical Group Stock Co Ltd along with its subsidiaries is engaged in the manufacturing and selling of pharmaceutical products. It is involved in the research and development of LXI-15028, a potassium-competitive acid blocker, which is in phase III development for the treatment of reflux esophagitis and other acid-related gastrointestinal diseases; and LXI-15029, an ATP mTOR kinase inhibitor that acts as potent and selective dual inhibitors of mTORC1 and mTORC2 that controls the process of tumor formation and growth. The company mainly operates in the People's Republic of China.

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Headlines

No Headlines